Scientists have unearthed a novel drug that shields nerve cells from damage caused by one of the most severe diseases, raising hope for a significant slowdown in its advancement. Initial research on M102 has shown enhancements in movement and nerve function in mice.
Experts are hopeful about trialing this medication on individuals with motor neurone disease (MND), a condition currently without a cure. MND disrupts the communication between motor neurones – nerve cells transmitting signals from the brain and spinal cord to muscles, leading to muscle weakness and stiffness affecting various bodily functions. In the UK, around 5,000 people suffer from MND, with most diagnosed individuals succumbing within two to five years of symptom onset.
M102, developed by researchers at the University of Sheffield’s Institute for Translational Neuroscience (SITraN) in collaboration with US biotech firm Aclipse Therapeutics, operates by activating defensive systems within cells named NRF2 and HSF1. These systems aid nerves in combating stress, reducing inflammation, and eliminating damaged proteins.
A preliminary study by SITraN, published in the journal Molecular Neurodegeneration, exhibited that M102 slowed MND progression and preserved muscle function in mice. It also shielded motor neurons from MND-induced damage in lab experiments. Professor Dame Pamela Shaw, SITraN’s director and study lead, expressed optimism about M102’s potential to significantly retard the disease’s progress.
The research team anticipates human trials for the drug. Dr. Richard Mead, senior lecturer in translational neuroscience at SITraN, emphasized the collaborative effort required to turn scientific discoveries into effective treatments. The team’s partnership with Aclipse Therapeutics aims to bridge the gap between research and clinical application, moving closer to a transformative MND treatment.
MND is a degenerative ailment impacting the nerves controlling movement, leading to progressive muscle weakness. While it can affect adults of any age, it is more prevalent in individuals over 50. Presently, there is no cure for MND, but treatments exist to manage symptoms.
Early symptoms of MND may resemble other less severe conditions, underscoring the importance of seeking medical advice if experiencing muscle weakness or spasms. The NHS advises individuals with specific symptoms to consult a GP for assessment and potential referral to a neurologist for further evaluation.
Opting for Daily Mirror as a ‘Preferred Source’ on Google News ensures swift access to valued news content.